ImmunoGen announces FDA Fast Track designation for mirvetuximab soravtansine
ImmunoGen announced the FDA has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for treatment of patients with medium to high folate receptor alpha-positive platinum-resistant ovarian cancer. June 18, 2018